Single, dual and triple agonists compared

Three generations of incretin research peptide, separated by how many receptors one sequence engages. What each additional receptor contributes, and what it costs in interpretability.

What the three classes are

Incretin research peptides divide by how many receptors a single sequence engages. That is the whole taxonomy, and it maps directly onto three generations of design.

Single agonists act at the GLP-1 receptor alone. Dual agonists add the receptor for glucose-dependent insulinotropic polypeptide, the other major incretin. Triple agonists add the glucagon receptor on top of both, which is a different kind of addition because glucagon is counter-regulatory rather than incretin.

A note on the catalogue labels, because they cause confusion. On this site the three classes are listed as GLP-1 (SM), GLP-2 (TR) and GLP-3 (RT). Those are catalogue names following a convention used across the research-peptide market, and the numbering refers to how many receptors are engaged. It is not a reference to the endogenous peptide GLP-2, which is a genuinely separate intestinotrophic hormone with nothing to do with dual incretin agonism, and there is no endogenous molecule called GLP-3 at all. Compound identity for any batch is available from research support with the Certificate of Analysis.

What each receptor contributes

The GLP-1 receptor is the best characterised of the three. Activation increases insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying and signals satiety through hindbrain and hypothalamic circuits. Everything else in the class is measured against this baseline.

The GIP receptor is the interesting one, because its role is still genuinely unsettled. It has a different tissue distribution from the GLP-1 receptor, notably in adipose tissue where GLP-1 receptors are sparse, and it also contributes to glucose-dependent insulin secretion. What remains contested in the literature is whether GIP receptor agonism or antagonism is the beneficial direction: credible programmes exist in both directions, which is unusual and worth knowing before designing around an assumption.

The glucagon receptor is counterintuitive. Glucagon raises hepatic glucose output, which opposes what the incretin arms do, but it also raises energy expenditure and drives hepatic fat oxidation. The hypothesis behind triple agonism is that the incretin arms offset the glycaemic effect while the expenditure effect is retained. Whether that holds depends entirely on the potency ratio between the three arms.

Why more receptors is not simply better

Each added receptor turns a fixed property into a design parameter. A single agonist has a potency; a dual agonist has a potency ratio; a triple agonist has two ratios that interact. That is why molecules within the triple-agonist class differ from one another considerably more than single agonists do, and why results obtained with one are a poor guide to another.

For a study design the consequence is attribution. An effect seen with a triple agonist could belong to any of three receptors or to an interaction between them, and no amount of care in measuring the effect resolves that on its own. Separating the arms requires the single and dual agonists in the same design, or selective antagonists, or both.

There is a related trap in reading the literature. Comparisons between classes are frequently made at doses matched by mass rather than by activity at a shared receptor, which makes any difference uninterpretable. Where a published comparison does not state how the arms were matched, it generally cannot answer the question it appears to answer.

Which class suits which question

If the question concerns the GLP-1 pathway itself — receptor signalling, beta cell response, gastric emptying, satiety circuitry — the single agonist is the right tool, and adding receptors only adds confounds.

If the question is what GIP receptor coverage contributes, the dual against single comparison is the minimum design, and it is the only way to attribute an effect to the GIP arm rather than to greater overall incretin activity.

If the question involves energy expenditure or hepatic lipid handling, the glucagon arm is the one doing the work, and the triple agonist is where that arm appears in this catalogue alongside full incretin coverage. For the glucagon arm paired with GLP-1 but without GIP, mazdutide and survodutide are the relevant comparators, and survodutide in particular has the more developed hepatic evidence base.

And if the question is whether an observed effect is incretin-mediated at all, the useful control is a compound that reduces food intake through an entirely separate receptor family: cagrilintide, an amylin analogue, does exactly that.

How all three are supplied

All three are supplied lyophilised in sealed vials across a range of strengths, and each is released against the Certificate of Analysis carrying the batch number printed on its label. The lab testing page documents how a batch is tested and released, and research support will confirm compound identity for a given batch on request.

Handling is similar across the class because the chemistry is similar: these are long acylated peptides that bind albumin, and they behave more like proteins than like short sequences. They are surface active, so vigorous agitation is avoided; aggregation and apparent solubility are concentration dependent, which is worth establishing before a quantitative assay rather than during one; and repeated freeze-thaw cycling degrades them. Sealed powder is stored below −18 °C and working solutions are prepared small, kept cold and used promptly. Diluents are under reconstitution supplies.

Research use only

Every compound discussed here is supplied by Amino Club as a laboratory reference material. None is a medicine, a supplement, or approved for human or veterinary use, and no dosing guidance or administration protocol is provided for any of them. The full terms are in the research use policy.